Seres Therapeutics (MCRB) Retained Earnings (2016 - 2025)
Seres Therapeutics (MCRB) has disclosed Retained Earnings for 11 consecutive years, with -$972.4 million as the latest value for Q4 2025.
- Quarterly Retained Earnings rose 0.58% to -$972.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$972.4 million through Dec 2025, up 0.58% year-over-year, with the annual reading at -$972.4 million for FY2025, 0.58% up from the prior year.
- Retained Earnings hit -$972.4 million in Q4 2025 for Seres Therapeutics, down from -$957.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $2000.0 in Q1 2023 to a low of -$1.0 billion in Q1 2024.
- Historically, Retained Earnings has averaged -$649.1 million across 5 years, with a median of -$889.1 million in 2023.
- Biggest five-year swings in Retained Earnings: surged 100.93% in 2023 and later crashed 50918500.0% in 2024.
- Year by year, Retained Earnings stood at -$60000.0 in 2021, then soared by 80.0% to -$12000.0 in 2022, then crashed by 8151858.33% to -$978.2 million in 2023, then rose by 0.01% to -$978.1 million in 2024, then rose by 0.58% to -$972.4 million in 2025.
- Business Quant data shows Retained Earnings for MCRB at -$972.4 million in Q4 2025, -$957.1 million in Q3 2025, and -$965.3 million in Q2 2025.